Nurix Therapeutics, Inc. NRIX

NRIX Company Overview

Nurix Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing targeted protein modulation therapies, primarily through technologies that leverage the ubiquitin-proteasome system. The company operates within the biotechnology and oncology drug development industries, with a strategic emphasis on protein degradation and protein stabilization approaches designed to treat cancer and immune-related diseases. Nurix’s core revenue sources have historically included collaboration agreements, licensing arrangements, and research funding from large pharmaceutical partners, while its long-term strategy centers on advancing proprietary clinical-stage therapeutics toward commercialization.

The company’s principal product development efforts involve targeted protein degraders, including orally bioavailable small molecules designed to recruit E3 ubiquitin ligases to eliminate disease-causing proteins. Nurix has developed proprietary platforms around DELigase, DNA-encoded library screening, and ligase engineering technologies. The company was founded in 2009 and later became publicly traded on Nasdaq under the ticker NRIX. Since its formation, Nurix has expanded from early-stage platform research into a clinical-stage biotechnology company with multiple investigational oncology programs and strategic collaborations with global pharmaceutical companies.